Although TAP is 1/2 Abbott, Abbott could divorce the problem from its operations. This would mean that the settlement would be paid out of TAP cash flow, not from Abbott reserves. The impact on Abbott would be the decreased TAP earnings flowing to Abbott. It is still a price that will have to be paid by Abbott shareholders, but just not as overt as the FDA fine. I don't believe the shelf offering announced yesterday has anything to do with this. It would most likely be used for the Knoll acquisition and other expenses.
I don't agree that the shelf offering was for Knoll purchase, however could be for additional working capital for the Knoll acquesion. The Knoll purchase was $7.8Billion, so they will need additional funding for that as they don't have the cash on hand and Knoll as I understand it is all cash.
However the TAP settlement could impact earnings of ABT for 200l as 50% of the TAP earnings go to ABT. The amount it will impact, depends on the settlement.